(Q40865037)

24 September 2017

1 reference

title

Innovative therapy for chronic myelogenous leukemia (English)

1 reference

24 September 2017

Miller JS

1

1 reference

24 September 2017

1 February 1998

1 reference

Hematology / Oncology Clinics of North America

24 September 2017

1 reference

24 September 2017

12

1 reference

24 September 2017

1

1 reference

24 September 2017

173-206

1 reference

Treatment of marrow stroma with interferon-alpha restores normal beta 1 integrin-dependent adhesion of chronic myelogenous leukemia hematopoietic progenitors. Role of MIP-1 alpha

24 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970502-5

7 January 2021

Interferon-alpha restores normal adhesion of chronic myelogenous leukemia hematopoietic progenitors to bone marrow stroma by correcting impaired beta 1 integrin receptor function

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970502-5

7 January 2021

Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970502-5

7 January 2021

Natural and antibody-dependent cellular cytotoxicity in chronic myeloid leukemia patients in remission

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970502-5

7 January 2021

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970502-5

7 January 2021

Unregulated proliferation of primitive chronic myeloid leukemia progenitors in the presence of normal marrow adherent cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970502-5

7 January 2021

Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970502-5

7 January 2021

Generation of donor-derived antileukemic cytotoxic T-lymphocyte responses for treatment of relapsed leukemia after allogeneic HLA-identical bone marrow transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970502-5

7 January 2021

Growth inhibition of clonogenic leukemic precursor cells by minor histocompatibility antigen-specific cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970502-5

7 January 2021

Potential therapeutic applications of antisense oligodeoxynucleotides in the treatment of chronic myelogenous leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970502-5

7 January 2021

Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970502-5

7 January 2021

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970502-5

7 January 2021

The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970502-5

7 January 2021

Lymphokine-activated killer cell activity Characteristics of effector cells and their progenitors in blood and spleen

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970502-5

7 January 2021

Cytotoxic lymphocytes require granzyme B for the rapid induction of DNA fragmentation and apoptosis in allogeneic target cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970502-5

7 January 2021

Tyrosine kinase inhibitor-induced differentiation of K-562 cells: alterations of cell cycle and cell surface phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970502-5

7 January 2021

Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970502-5

7 January 2021

MHC class I alloantigen specificity of Ly-49+ IL-2-activated natural killer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970502-5

7 January 2021

Express yourself or die: peptides, MHC molecules, and NK cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970502-5

7 January 2021

Clinical adoptive chemoimmunotherapy with allogeneic alloactivated HLA-haploidentical lymphocytes: controlled induction of graft-versus-host-reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970502-5

7 January 2021

Comparison of different ribozymes for efficient and specific cleavage of BCR/ABL related mRNAs.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970502-5

7 January 2021

Specificity of HLA class I antigen recognition by human NK clones: evidence for clonal heterogeneity, protection by self and non-self alleles, and influence of the target cell type

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970502-5

7 January 2021

NKB1: a natural killer cell receptor involved in the recognition of polymorphic HLA-B molecules

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970502-5

7 January 2021

Inhibition of clonogenic growth of fresh leukemia cells by unstimulated and IL-2 stimulated NK cells of normal donors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970502-5

7 January 2021

In search of the 'missing self': MHC molecules and NK cell recognition

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970502-5

7 January 2021

Origin and function of adherent lymphokine activated killer cells in patients with chronic myeloid leukaemia who relapse following bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970502-5

7 January 2021

Minor histocompatibility antigen-specific cytotoxic T cell lines, capable of lysing human hematopoietic progenitor cells, can be generated in vitro by stimulation with HLA-identical bone marrow cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970502-5

7 January 2021

Autologous transplants for chronic myelogenous leukaemia: results from eight transplant groups

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970502-5

7 January 2021

Cytotoxic activity against HIV-infected monocytes by recombinant interleukin 2-activated natural killer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970502-5

7 January 2021

Identification of four subsets of human CD3-CD16+ natural killer (NK) cells by the expression of clonally distributed functional surface molecules: correlation between subset assignment of NK clones and ability to mediate specific alloantigen recogn

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970502-5

7 January 2021

P58 molecules as putative receptors for major histocompatibility complex (MHC) class I molecules in human natural killer (NK) cells. Anti-p58 antibodies reconstitute lysis of MHC class I-protected cells in NK clones displaying different specificitie

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970502-5

7 January 2021

Transforming growth factor-beta complexes with thrombospondin

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970502-5

7 January 2021

Constitutive expression of high affinity interleukin 2 receptors on human CD16-natural killer cells in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970502-5

7 January 2021

Relative roles of natural killer- and T cell-mediated anti-leukemia effects in chronic myelogenous leukemia patients treated with interferon-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970502-5

7 January 2021

Cellular immunological defects of chronic myelogenous leukaemics: partial dependence on busulphan therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970502-5

7 January 2021

Partial correction of defective generation of lymphokine-activated killer cells in patients with chronic myelogenous leukaemia after in vivo treatment with interferon-alpha (Wellferon).

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970502-5

7 January 2021

Population dynamics of human activated natural killer cells in culture.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970502-5

7 January 2021

Production of human natural killer cells for adoptive immunotherapy using a computer-controlled stirred-tank bioreactor

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970502-5

7 January 2021

Natural killer cell proliferation is dependent on human serum and markedly increased utilizing an enriched supplemented basal medium

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970502-5

7 January 2021

Natural killer cell receptors: the offs and ons of NK cell recognition.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970502-5

7 January 2021

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970502-5

7 January 2021

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970502-5

7 January 2021

Thrombospondin causes activation of latent transforming growth factor-beta secreted by endothelial cells by a novel mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970502-5

7 January 2021

Natural killer and lymphokine-activated killer cells require granzyme B for the rapid induction of apoptosis in susceptible target cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970502-5

7 January 2021

Generation of activated natural killer (A-NK) cells in patients with chronic myelogenous leukaemia and their role in the in vitro disappearance of BCR/abl-positive targets

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970502-5

7 January 2021

Human granzyme B is essential for DNA fragmentation of susceptible target cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970502-5

7 January 2021

Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970502-5

7 January 2021

Biology of natural killer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970502-5

7 January 2021

Interferon-alpha restores the deficient expression of the cytoadhesion molecule lymphocyte function antigen-3 by chronic myelogenous leukemia progenitor cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970502-5

7 January 2021

Induction and characterization of cytotoxic T-lymphocytes recognizing a mutated p21ras peptide presented by HLA-A*0201.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970502-5

7 January 2021

Macrophage inflammatory protein 1 alpha, interleukin 3 and diffusible marrow stromal factors maintain human hematopoietic stem cells for at least eight weeks in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970502-5

7 January 2021

Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia. Decreased adhesion to stroma and fibronectin but increased adhesion to the basement membrane components laminin and collagen type IV

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970502-5

7 January 2021

Purified primitive human hematopoietic progenitor cells with long-term in vitro repopulating capacity adhere selectively to irradiated bone marrow stroma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970502-5

7 January 2021

Lymphokine-activated killer cells in rats. III. A simple method for the purification of large granular lymphocytes and their rapid expansion and conversion into lymphokine-activated killer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970502-5

7 January 2021

Molecular clones of the p58 NK cell receptor reveal immunoglobulin-related molecules with diversity in both the extra- and intracellular domains

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970502-5

7 January 2021

Natural killer lymphocyte blast crisis of chronic myelogenous leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970502-5

7 January 2021

Allogeneic NK cells as potent antileukemic effector cells after allogeneic bone marrow transplantation in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970502-5

7 January 2021

10.1016/S0889-8588(05)70502-5

Identifiers

DOI

1 reference

24 September 2017

1 reference

PubMed ID

9523231